Form 4: Krystal Biotech CAO Reports Equity Transactions

Krystal Biotech's Chief Accounting Officer, Kathryn Romano, reported a series of equity transactions including vesting of performance and restricted stock units, tax-related dispositions, a planned stock sale, and new equity grants.

Summary

• Kathryn Romano, Chief Accounting Officer of Krystal Biotech, Inc., reported multiple equity transactions.
• On February 27, 2026, 7,500 shares of common stock vested from Performance Stock Units (PSUs) granted on February 29, 2024, following the achievement of performance criteria.
• Concurrently, 3,262 shares of common stock were surrendered to the Company for tax withholding related to the PSU vesting at a price of $275.64 per share.
• Also on February 27, 2026, 550 shares of common stock vested from Restricted Stock Units (RSUs) granted on February 28, 2025.
• An additional 240 shares of common stock were surrendered to the Company for tax withholding related to the RSU vesting at a price of $275.64 per share.
• On March 2, 2026, 750 shares of common stock were sold at $267.60 per share under a Rule 10b5-1 trading plan adopted on November 6, 2025, which has now terminated.
• Romano was granted 13,575 stock options with an exercise price of $275.64, vesting in four equal annual installments starting February 27, 2027, and expiring on February 26, 2036.
• She also received a grant of 5,442 Restricted Stock Units (RSUs), vesting in four equal annual installments starting February 27, 2027.
• Following these transactions, Romano directly beneficially owns 22,366 shares of common stock, 1,650 Restricted Stock Units, 13,575 Stock Options, and 5,442 new Restricted Stock Units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a largely neutral filing, reflecting standard executive compensation activities. The vesting of performance-based units and new equity grants are positive for executive retention and alignment, while tax-related sales and a planned disposition are routine.

Positives

• Achievement of performance criteria for 15,000 PSUs granted in February 2024, leading to the vesting of the remaining 7,500 units.
• Grant of 13,575 new stock options, providing future equity upside potential.
• Grant of 5,442 new Restricted Stock Units, aligning executive incentives with long-term company performance.

Negatives

• Disposition of 3,262 shares and 240 shares for tax withholding, reducing direct common stock ownership.
• Sale of 750 shares under a Rule 10b5-1 plan, indicating a planned reduction in direct common stock holdings.

Future Outlook

Kathryn Romano's equity compensation includes future vesting schedules for newly granted stock options and restricted stock units, with the first installments set to vest on February 27, 2027. The stock options have an expiration date of February 26, 2036.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as those reported in this Form 4, are common for executives receiving equity compensation. The use of a Rule 10b5-1 plan for stock sales indicates a pre-arranged disposition strategy, which is a standard practice for insiders to avoid accusations of trading on material non-public information. The grants of new stock options and RSUs are typical components of executive compensation packages designed to align management interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The transactions represent routine executive compensation and planned stock sales, which are generally expected and do not indicate significant shifts in company strategy or financial health. The new grants align executive interests with long-term shareholder value.

Next Steps

• First installment of 13,575 stock options to vest on February 27, 2027.
• First installment of 5,442 Restricted Stock Units to vest on February 27, 2027.
• Remaining 1,650 Restricted Stock Units (from 2/28/2025 grant) to vest in subsequent annual installments.
• Stock options granted on February 27, 2026, will expire on February 26, 2036.

Key Dates

Keywords

Krystal Biotech, KRYS, Kathryn Romano, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Performance Stock Units, Equity Compensation, Rule 10b5-1, Officer Transactions